Skip to main content
Top
Published in: Diagnostic Pathology 1/2020

01-12-2020 | Ovarian Cancer | Research

Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America

Authors: Peter F. Rambau, Martin Köbel, Derek Tilley, Alex Mremi, Robert Lukande, William Muller

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Ovarian cancer is a spectrum of several histologically distinct tumor types that differ in etiology, response to therapy, and prognosis. In resource-limited settings, the diagnosis of ovarian cancer can be challenging. This study describes the distribution of ovarian cancer tumor types in East Africa as well as assessing the diagnostic accuracy by using contemporary methods.

Methods

Data from 210 women identified from the records with a diagnosis of ovarian cancer in a period of 15 years were included. Two tissue microarrays were constructed and stained with 20 antibodies relevant to ovarian cancer subtyping. An integrated diagnosis was reached by the review of full Haematoxylin and Eosin stained sections, with consideration of immunohistochemical results. The integrated diagnoses were compared with the original diagnoses, and the degree of agreement was evaluated by percentage and Kappa statistics.

Results

Though limited by selection bias, the results suggest lower rates of ovarian cancer in East Africa compared to a North American population from Alberta, Canada. There was a higher proportion of sex cord stromal tumors and germ cell tumors in the East African population. Diagnostic accuracy for main ovarian tumor type categories was substantial (Kappa 0.70), but only fair for specific ovarian carcinoma histotypes (Kappa 0.34). Poor Haematoxylin and Eosin stain was the main factor hindering the correct diagnosis, which was not related to tissue processing.

Conclusions

In a resource-limited setting, where immunohistochemistry is not routinely carried out, diagnostic accuracy for the main categories of ovarian carcinoma is substantial and could be further improved by standardization of the basic Haematoxylin and Eosin stain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ. 1993;121:1–806. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ. 1993;121:1–806.
2.
go back to reference Stefan DC, Elzawawy AM, Khaled HM, Ntaganda F, Asiimwe A, Addai BW, et al. Developing cancer control plans in Africa: examples from five countries. Lancet Oncol. 2013;14(4):e189–95.PubMed Stefan DC, Elzawawy AM, Khaled HM, Ntaganda F, Asiimwe A, Addai BW, et al. Developing cancer control plans in Africa: examples from five countries. Lancet Oncol. 2013;14(4):e189–95.PubMed
4.
go back to reference Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004-2008). Int J Cancer. 2015;137(9):2053–9.PubMed Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004-2008). Int J Cancer. 2015;137(9):2053–9.PubMed
5.
go back to reference Sung PL, Chang YH, Chao KC, Chuang CM. Task force on systematic R, meta-analysis of ovarian C. global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014;133(2):147–54.PubMed Sung PL, Chang YH, Chao KC, Chuang CM. Task force on systematic R, meta-analysis of ovarian C. global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014;133(2):147–54.PubMed
6.
go back to reference Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39(8):1239–51.PubMed Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39(8):1239–51.PubMed
7.
go back to reference Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17(Suppl 8):viii15–23.PubMed Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17(Suppl 8):viii15–23.PubMed
8.
go back to reference African Pathologists' Summit Working G. Proceedings of the African pathologists summit; march 22-23, 2013; Dakar, Senegal: a summary. Arch Pathol Lab Med. 2015;139(1):126–32. African Pathologists' Summit Working G. Proceedings of the African pathologists summit; march 22-23, 2013; Dakar, Senegal: a summary. Arch Pathol Lab Med. 2015;139(1):126–32.
9.
go back to reference Rambau PF. Pathology practice in a resource-poor setting: Mwanza. Tanzania Arch Pathol Lab Med. 2011;135(2):191–3.PubMed Rambau PF. Pathology practice in a resource-poor setting: Mwanza. Tanzania Arch Pathol Lab Med. 2011;135(2):191–3.PubMed
10.
go back to reference Adesina A, Chumba D, Nelson AM, Orem J, Roberts DJ, Wabinga H, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152–7.PubMed Adesina A, Chumba D, Nelson AM, Orem J, Roberts DJ, Wabinga H, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152–7.PubMed
11.
go back to reference Kobel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An Immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430–41.PubMedPubMedCentral Kobel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An Immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430–41.PubMedPubMedCentral
12.
go back to reference Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.PubMed Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.PubMed
13.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMed
14.
go back to reference Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144(2):405–13.PubMed Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144(2):405–13.PubMed
15.
go back to reference Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–23.PubMed Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–23.PubMed
16.
go back to reference Gilks CB, Kommoss F. Ovarian carcinoma Histotypes: their emergence as important prognostic and predictive markers. Oncology (Williston Park). 2016;30(2):178–9. Gilks CB, Kommoss F. Ovarian carcinoma Histotypes: their emergence as important prognostic and predictive markers. Oncology (Williston Park). 2016;30(2):178–9.
17.
go back to reference Cramer SF, Roth LM, Ulbright TM, Mazur MT, Nunez CA, Gersell DJ, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med. 1987;111(9):819–29.PubMed Cramer SF, Roth LM, Ulbright TM, Mazur MT, Nunez CA, Gersell DJ, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med. 1987;111(9):819–29.PubMed
18.
go back to reference Hernandez E, Bhagavan BS, Parmley TH, Rosenshein NB. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol. 1984;17(1):117–23.PubMed Hernandez E, Bhagavan BS, Parmley TH, Rosenshein NB. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol. 1984;17(1):117–23.PubMed
19.
go back to reference Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS. 1991;99(4):353–8.PubMed Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS. 1991;99(4):353–8.PubMed
20.
go back to reference Kobel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 2010;34(7):984–93.PubMed Kobel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 2010;34(7):984–93.PubMed
21.
go back to reference Singh N, Gilks CB. The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. Histopathology. 2017;70(1):56–69.PubMed Singh N, Gilks CB. The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. Histopathology. 2017;70(1):56–69.PubMed
22.
go back to reference Kobel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, et al. Ovarian carcinoma Histotype: strengths and limitations of integrating morphology with Immunohistochemical predictions. Int J Gynecol Pathol. 2019;38(4):353–62.PubMedPubMedCentral Kobel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, et al. Ovarian carcinoma Histotype: strengths and limitations of integrating morphology with Immunohistochemical predictions. Int J Gynecol Pathol. 2019;38(4):353–62.PubMedPubMedCentral
23.
go back to reference Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.PubMed Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.PubMed
24.
go back to reference Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5):480 e1–8.PubMed Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5):480 e1–8.PubMed
25.
go back to reference Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.PubMed Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.PubMed
26.
go back to reference Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–4.PubMed Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–4.PubMed
27.
go back to reference Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74(6):921–6.PubMed Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74(6):921–6.PubMed
28.
go back to reference Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and Appendiceal origin from primary ovarian tumors of mucinous or Endometrioid type. Am J Surg Pathol. 2016;40(3):419–32.PubMed Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and Appendiceal origin from primary ovarian tumors of mucinous or Endometrioid type. Am J Surg Pathol. 2016;40(3):419–32.PubMed
29.
go back to reference Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019;32(12):1834-46. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019;32(12):1834-46.
30.
go back to reference Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27(2):161–74.PubMed Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27(2):161–74.PubMed
31.
go back to reference Ramalingam P. Morphologic, Immunophenotypic, and molecular features of epithelial ovarian Cancer. Oncology (Williston Park). 2016;30(2):166–76. Ramalingam P. Morphologic, Immunophenotypic, and molecular features of epithelial ovarian Cancer. Oncology (Williston Park). 2016;30(2):166–76.
32.
go back to reference Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102–16.PubMed Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102–16.PubMed
33.
go back to reference Kupryjanczyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, Plisiecka-Halasa J, Szafron L, Podgorska A, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. A pilot study. Pol J Pathol. 2013;64(4):238–46.PubMed Kupryjanczyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, Plisiecka-Halasa J, Szafron L, Podgorska A, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. A pilot study. Pol J Pathol. 2013;64(4):238–46.PubMed
34.
go back to reference Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–43.PubMed Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–43.PubMed
35.
go back to reference Niwa Y, Yamamuro O, Kato N, Tsuzuki T. Two cases of primary ovarian neuroblastoma arising from mature cystic teratomas. Gynecol Oncol Case Rep. 2013;5:58–60.PubMedPubMedCentral Niwa Y, Yamamuro O, Kato N, Tsuzuki T. Two cases of primary ovarian neuroblastoma arising from mature cystic teratomas. Gynecol Oncol Case Rep. 2013;5:58–60.PubMedPubMedCentral
36.
go back to reference Singh M, Arora P, Singh S, Bohara S, Khurana N, Zutshi V, et al. Adult neuroblastoma of the ovary: a rare tumor with review of literature. J Cancer Res Ther. 2010;6(3):367–9.PubMed Singh M, Arora P, Singh S, Bohara S, Khurana N, Zutshi V, et al. Adult neuroblastoma of the ovary: a rare tumor with review of literature. J Cancer Res Ther. 2010;6(3):367–9.PubMed
37.
go back to reference Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56.PubMedPubMedCentral Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56.PubMedPubMedCentral
38.
go back to reference Na K, Sung JY, Kim HS. TP53 mutation status of Tubo-ovarian and peritoneal high-grade serous carcinoma with a wild-type p53 Immunostaining pattern. Anticancer Res. 2017;37(12):6697–703.PubMed Na K, Sung JY, Kim HS. TP53 mutation status of Tubo-ovarian and peritoneal high-grade serous carcinoma with a wild-type p53 Immunostaining pattern. Anticancer Res. 2017;37(12):6697–703.PubMed
39.
go back to reference Kobel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247–58.PubMedPubMedCentral Kobel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247–58.PubMedPubMedCentral
40.
go back to reference Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14(9):853–62.PubMedPubMedCentral Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14(9):853–62.PubMedPubMedCentral
41.
go back to reference Rambau P, Kelemen LE, Steed H, Quan ML, Ghatage P, Kobel M. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. Int J Mol Sci. 2017;18(3):515. Rambau P, Kelemen LE, Steed H, Quan ML, Ghatage P, Kobel M. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. Int J Mol Sci. 2017;18(3):515.
42.
go back to reference Assem H, Rambau PF, Lee S, Ogilvie T, Sienko A, Kelemen LE, et al. High-grade Endometrioid carcinoma of the ovary: a Clinicopathologic study of 30 cases. Am J Surg Pathol. 2018;42(4):534–44.PubMed Assem H, Rambau PF, Lee S, Ogilvie T, Sienko A, Kelemen LE, et al. High-grade Endometrioid carcinoma of the ovary: a Clinicopathologic study of 30 cases. Am J Surg Pathol. 2018;42(4):534–44.PubMed
43.
go back to reference Rambau PF, Duggan MA, Ghatage P, Warfa K, Steed H, Perrier R, et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology. 2016;69(2):288–97.PubMed Rambau PF, Duggan MA, Ghatage P, Warfa K, Steed H, Perrier R, et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology. 2016;69(2):288–97.PubMed
Metadata
Title
Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America
Authors
Peter F. Rambau
Martin Köbel
Derek Tilley
Alex Mremi
Robert Lukande
William Muller
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-01000-3

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue